Summary of findings 13. Paroxetine compared with mirtazapine for depression.
| Paroxetine compared with mirtazapine for depression | ||||||
| Patient or population: patients with depression Settings: in‐ and out‐patients Intervention: paroxetine Comparison: mirtazapine | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Mirtazapine | Paroxetine | |||||
| Failure to respond at endpoint (6‐12 weeks) | 509 per 1000 | 554 per 1000 (483 to 625) | OR 1.20 (0.90 to 1.61) | 766 (4 studies) | ⊕⊕⊕⊝ moderate1 | |
| Failure to respond at 1‐4 weeks | 735 per 1000 | 869 per 1000 (797 to 918) | OR 2.39 (1.42 to 4.02) | 726 (3 studies) | ⊕⊕⊕⊝ moderate1 | |
| Failure to respond at 16‐24 weeks | Study population | OR 1.41 (0.81 to 2.48) | 726 (3 studies) | ⊕⊕⊕⊝ moderate1 | ||
| 735 per 1000 | 869 per 1000 (797 to 918) | |||||
| Moderate | ||||||
| Failure to remit at endpoint | 597 per 1000 | 692 per 1000 (626 to 753) | OR 1.52 (1.13 to 2.06) | 766 (4 studies) | ⊕⊕⊕⊝ moderate1 | |
| SMD at endpoint | The mean SMD at endpoint in the intervention groups was 0.33 standard deviations higher (0.08 to 0.58 higher) | 246 (1 study) | ⊕⊕⊕⊝ moderate1 | The point estimate of the effect size corresponds to a small effect according to Cohen 1992. | ||
| Failure to complete ‐ any cause ‐ | 306 per 1000 | 357 per 1000 (286 to 434) | OR 1.26 (0.91 to 1.74) | 726 (3 studies) | ⊕⊕⊕⊝ moderate1 | |
| Participants with at least some Side Effects | 743 per 1000 | 756 per 1000 (687 to 813) | OR 1.07 (0.76 to 1.50) | 726 (3 studies) | ⊕⊕⊕⊝ moderate1 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; SMD: standardized mean difference; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Blinding stated but not tested. No information on randomisation procedures and allocation concealment.